LIPID-PROTEIN/YSTEMS OF TRANSPORTATION OF BLOOD CIOLESTEROL IN PATIENTS WITH SYSTEMIClUPUS ERYTHEMATOSUS DEPEND1N5AJN ANTIPHOSPHOLIPID SYNDROME
https://doi.org/10.14412/1995-4484-2001-465
Abstract
Objective. To stude the indices of lipid-protein blood spectrum in SLE pts with A PS as one of the risk factors of atherosclerosis development. Material and methods. 60 pts (45 females and 15 males) with definite SLE (ARA criteria, 1982) were examined; age 15-44 (median age 28.9+8.1; M+G), disease duration from 2 months to 28 years (median 8.6+6.6 years) APS was diagnosed in 39 out of them( G.R.V.Huges and E.N.Harris criteria, 1986) with subsequent isolation of Wr' -wKable, possible and unreliable A PS; thrombotic complications were observed in 23 out of 39 SLE pts with APS. Control group was composed of 35 practically healthy persons without risk factors of atherosclerosis and related diseases development. Results. There were no difference in the levels of cholesterol, triglycerides low density lipoproteid cholesterol and apolipoprotein В in SLE pts with APS as compared with SLE pts without APS. Concentration of high density lipoproteid cholesterol (HD LP C) and apolipoprotein AI (apo A!) was higher in SLE pts with APS as compared with SLE pis without APS and reached for HD LPC- 46. I±11.0mg/dl against 40.5±8.1 mg/dl, for apoAl - 133.7±28.1 tng/cll against 118.5±28.2 mg/dl correspondingly (p=0.04 and p-0.05). There was no difference in the content oJHD LP phospholipids in the group of SLE pts with and without APS. The level ofHD LP phospholipids in the group of SLE pts with APS was lower (91, 8±21.2 mg/dl) as compared to the control group (131.8+3 5.1 mg/dl)(p=0.001), The relation ofHD LP С/apoAl in SLE pts with APS: 0.35+0.06 against 0.38±0.08 in persons from the control group (p-0.04). With the decreased level ofHD LP in basic groups of pts as,compared with control statistically reliable difference of all HD LP phospholipids was found (p<0.001). Иге level of apoAl was lower in pts with unreliable APS as compared with such in pts with definite APS (137.4+26,6 mg/dl and 103.8±23.5 mg/dl (p-0.002). Conclusion. In SLE pts with APS there are interrelated pathogenic mechanisms, which could lead to thrombotic complications as well as to atherosclerotic vascular damage.
References
1. <div><p>Алекберова З.С., Насонова В.А. Липидный обмен при длительном лечении кортикостероидами больных кол- лагенозами. Сов.медицина, 1967, 10,32-36.</p><p>Герасимова Е.Н., Перова Н.В. Саморегуляция функционального состояния ЛВП и нарушение ее при гмпо- альфахолестеринемии. Вопр. мед. химии, 1985 I, 32-40.</p><p>Герасимова Е.Н., Никитин Ю.П., Озерова И.Н. Некоторые причины изменений фосфолнпидного состава ЛВП при гипоальфахолестеринемии. Вопр. мед. химии, 1985.3.132-136.</p><p>Кейтс М. Фосфолипиды В кн. “Техника липидологии”. М., “Мир”, 1975,257-270.</p><p>Карпов Р.С., Канская Н.В., Осипов С.Г. Роль иммунной системы в развитии гиперлипопротендемий. Томск: Изд-во Томск. Гос. ун-та, 1990, 168.</p><p>Карпов Р.С., Дудко В.А, Атеросклероз Томск: STT, 1998,651.</p><p>Насонов Е.Л., Карпов Ю.А., Алекберова З.С. и соавт. Антифосфолипидный синдром: кардиологические аспекты. Тер. архив, 1993, I, 80-86</p><p>Насонов Е.Л., Баранов А.А., Шилкина Н.П., Алекберова З.С. Патология сосудов при антифосфолипид- иом синдроме. Москва-Ярославль, 1995, 162</p><p>Насонов Е.Л. Атеротромбоз при ревматических заболеваниях: анализ патогенеза. Тер. архив. 1998,9.9295.</p><p>Насонов Е.Л. Баранов А.А., Шилкина Н.П, Васкули- ты и васкулопатин. Ярославль, 1999. 616.</p><p>Насонова В.А. Системная красная волчанка. М. Медицина, 1972.</p><p>Перова Н.В. Возможности применения метода электрофореза на различных поддерживающих средах для анализа спектра липопротеидов плазмы крови. В кн. "Дислипопротеидемии и ишемическая болезнь сердца”. М., Медицина, 1980,103-1II.</p><p>Титов В.Н. Биохимические факторы риска коронарного атеросклероза. Тер. архив, 1991.4, 141-146.</p><p>Юну П., Саложин К.В., Насонов Е.Л., Насонова В.А. Клиническое значение антител к сосудистому эндотелию. Клин, медицина, 1995,5, 5-7.</p><p>Alaicon-Segovia D. Antiphospholipid syndrome in SLE. Abslr. of III Intern. Conference on SLE. Lupus, 1992, I, suppl., 13,</p><p>Amengual O., Atsumi Т., Khamashta M.A., et al. Antibodies against oxidized low-density lipoprotein (ox- LDL) in 107 patients with antiphospholipid syndrome (APS). Arthritis Rheum., 1996, 39, suppl., 96.</p><p>Asherson R.A., Cervera R. Antiphospholipid antibodies and the heart: lessons and pitfals for cardiologist. Circulation, 1991, 84, 920-922.</p><p>Beamont I.L., Beamont V. Dyslipoproteimias and autoimmunity (Human Plasma Lipoproteins). Eds. I. C. Fruchat. J. Shepherd. Berlini waiter de Gruyter, 1989, 281-307.</p><p>Cabiedes J., Cabral A.R., Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta2-glycoprotein-l than with antiphospholipid antibodies. J.Rheumatol., 1995, 22, 1899-1906.</p><p>Del Papa N., Guidali L., Spatola L., et al. Relationship between antiphospholipid and anti-endothelial cell antibodies 111: beta2-glycoprotein mediates the antibody binding to endothelial membrane and induces the expression of adhesion molecules. Clin. Exp. Rheumatol., 1995,13,179-185.</p><p>Esmon C.T. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surphase. Faseb J. 1995, 9, 946-955.</p><p>Ettinger W.H., Goldberg A.P., Appelbaum-Bowden D., Hazzard W.R. Dislipoproteinemia in systemic lupus erythematosus. Am. J. Med., 1987, 83, 503-508.</p><p>Isenberg D.A., Horsfall A. Systemic lupus erythemato- sus-adull onset. In: Maddison P.J., Isenberg D.A., Woo P., Glass D.N eds. Oxford Textbook of Rheumatology, Oxford University Press, 1993, 733-755.</p><p>Fu.kumoto S., Tsumagari Т., Kinjo М., Tanaka K. Coro. nary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol.Jpn., 1987,37, 1-9.</p><p>Fournier N., Moya., Burkey B. Role of HDL phosholip- id in efflux of cell cholesterol to whole serum studies with human apo A1 transgenic rats. J. Lipid. Res. 1996, 37,1704-1711.</p><p>Garrido J.A., Peromingo J.A.D., Sesma P., Pia G. More about the link between thrombosis and atherosclerosis in autoimmune disease: triglicerides and risk for thrombosis in patients with antiphospholipid antibodies. J. Rheumatol., 1994,21,2394.</p><p>Harris E.M., Gharavi A.E., Patel S.P. Evaluation of the anti-cardiolipin antibody test: report of an International workshop held 4 April 1986. Clin.Exp.Immunol., 1987, 6S. 215-222.</p><p>Lachita R.G., Rivkin E., Cavanagh I. Romano P. Low' levels of total cholesterol, high density lipoprotein and apolipoprotein AI in assotiation with anticardiolipin antibodies in patients with SLE. Arlhr. Rheum., 1993. 36,1566-1674.</p><p>Manual of Laboratory Operations: Lipid Research Clinics Program. Washington., 1974. I., 75-625. Oosling J.D., Derksen R.W.M., Bobbink I.W.G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood, 1993, 81, 2618-2625.</p><p>Prevention of Coronary Heart Disease: Scientific background and new clinical guidelines. Recommendation of European Atherosclerosis Society prepared by the International Task Force for prevention of Coronary Heart Disease. Nutr. Metab. Cardiovasc. Dis., 1992, 2. 113-156.</p><p>Prevention of Coronary Heart Disease in clinical practice. Recommendation of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertenti in Eur. Heart J., 1994,15.1300-1331.</p><p>vanborg A., Svennerholm L. Plasma total lipid cholesterol, triglycerides, phospholipids and free fatty acids in a healthy Scandinavian population. Acta ined. Scand, 1961,169,43-46.</p></div><br />
Review
For citations:
Popkova T.V., Alekberova Z.S., Reshetniak T.M., Nassonov E.L., Nassonova V.A. LIPID-PROTEIN/YSTEMS OF TRANSPORTATION OF BLOOD CIOLESTEROL IN PATIENTS WITH SYSTEMIClUPUS ERYTHEMATOSUS DEPEND1N5AJN ANTIPHOSPHOLIPID SYNDROME. Rheumatology Science and Practice. 2001;39(5):12-18. (In Russ.) https://doi.org/10.14412/1995-4484-2001-465
Views:
784
Email this article 